Forget Moderna: This Biotech Juggernaut Is a Way Better Buy Right Now

Moderna (NASDAQ:MRNA) is backmost successful the headlines aft ripping 63.17% higher twelvemonth to day connected a astonishment Q1 gross triple and renewed pipeline excitement. But the underlying communicative deserves a person look.

The Moderna Story Has Not Changed

Strip distant the bounce and the fundamentals archer the aforesaid communicative semipermanent investors person heard for 3 years running. Full-year 2025 gross collapsed to $1.94 billion, a astir 40% drop, and management's ain 2026 guidance calls for up to 10% maturation disconnected that depressed base. Roughly 80% of Q1 2026 income came from extracurricular the U.S., and the full franchise is inactive efficaciously a azygous COVID product.

Meanwhile, currency is bleeding. Year-end currency is projected to autumn from $8.1 cardinal astatine the extremity of 2025 to $4.5 cardinal to $5.0 cardinal by year-end 2026. Management drew $600 cardinal connected a recognition facility. Q1 GAAP nett nonaccomplishment widened to $1.34 billion. There is nary dividend, nary buyback, and the upcoming catalysts (the August 5, 2026 flu vaccine PDUFA, melanoma readouts, norovirus Phase 3) are binary catalysts alternatively than net drivers. Polymarket traders priced a 100% implied probability of the Q1 miss earlier resolution. That is what a crowded header commercialized looks like.

The expert who called NVIDIA successful 2010 conscionable named his apical 10 stocks and Gilead Sciences wasn't 1 of them. Get them present FREE.

The Gilead Alternative

The smarter rotation is into Gilead Sciences (NASDAQ:GILD), which trades astatine a guardant net aggregate of 15 with a 2.46% dividend output and a marketplace headdress adjacent $162 billion. Three reasons this is the amended semipermanent holding for a status portfolio.

1. A cash-flow instrumentality generating existent escaped currency flow. The HIV franchise grew 10% to $5.03 cardinal successful Q1 2026, with Biktarvy unsocial bringing successful $3.36 cardinal for the quarter. Patent extortion connected Biktarvy was extended to April 2036, meaning nary large nonaccomplishment of exclusivity for a afloat decade. Non-GAAP merchandise gross borderline expanded 200 ground points to 87.5%, and Q1 escaped currency travel deed $2.427 billion, up 237.08% twelvemonth implicit year.